Results 11 to 20 of about 1,176 (166)
Cardiovascular Diabetology, 2023 Sodium-glucose co-transporter-2 inhibitors are used in the treatment of diabetes but are also emerging as cardioprotective agents in heart diseases even in the absence of type 2 diabetes.
Julia Hoehlschen +3 more
doaj +1 more source
IJU Case Reports, 2019 Introduction Sodium glucose co‐transporter 2 inhibitors constitute a new class of antidiabetic medication. Sodium glucose co‐transporter 2 inhibitors have been shown to exert anticancer effects.
Keita Izumi +4 more
doaj +1 more source
Лечащий Врач, 2022 Impaired kidney function has a negative impact on the course of heart failure in both patients with and without diabetes mellitus. Therefore, the development and study of the effectiveness of methods for the treatment of chronic heart failure, especially
E. V. Kovalenko +2 more
doaj +1 more source
International Journal of Nephrology and Renovascular Disease, 2023 Rey Isidto,1 Romina Danguilan,2 Oscar Naidas,3 Russell Vilanueva,2 Mel-Hatra Arakama,2 Layla Marie Paraiso2 1HealthLink Medical, Surgical, Dental Clinics and Diagnostic Center, Iloilo City, Iloilo, Philippines; 2Department of Adult Nephrology, National ...
Isidto R +5 more
doaj
Sodium-glucose co-transporter-2 inhibitors: A cardiovascular outcome trial analysis
Perspectives in Clinical Research, 2021 Cardiovascular outcome trials (CVOTs) have to be done by sponsors who wish to launch new antidiabetic drugs in the US, since the December 2008 US Food and Drug Administration ruling, which was subsequently accepted by the European Medicines (Evaluation ...
Viraj Ramesh Suvarna
doaj +1 more source
Cardiology Journal, 2023 Several mechanisms have been suggested to explain positive cardiovascular effects observed in studies with sodium-glucose co-transporter 2 (SGLT2) inhibitors.
Jacek Kubica +24 more
doaj +1 more source
Sodium glucose co-transporter 2 inhibitors in patients with resistant hypertension: a case study
JRSM Open, 2016 Sodium glucose co-transporter 2 inhibitors lower blood pressure by osmotic diuresis and can be considered in diabetic patients with resistant hypertension.
Amira Obeid +3 more
doaj +1 more source
Impact of SGLT2 inhibitors treatment on the chronic kidney disease in people with type 2 diabetes
Journal of Education, Health and Sport, 2022 Diabetes is the most common cause of CKD (chronic kidney disease). CKD is also one of the most important diabetic complication. SGLT2 (sodium glucose co‐transporter‐2) inhibitors are new class of medication used to lower high blood glucose level in ...
Marcin Czarkowski +3 more
doaj +1 more source
Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease
The Scientific World Journal, 2015 SGLT2 inhibitors are new antihyperglycaemic agents whose ability to lower glucose is directly proportional to GFR. Therefore, in chronic kidney disease (CKD) the blood glucose lowering effect is reduced.
L. Zanoli +6 more
doaj +1 more source
A case report of euglycemic ketoacidosis due to dapagliflozin treatment
Turkish Journal of Internal Medicine, 2021 Diabetic ketoacidosis (DKA) is a leading cause of mortality and morbidity in type 2 diabetic patients. Sodium-glucose co-transporter (SGLT-2) inhibitors are a new antidiabetic treatment class that increases the renal excretion of glucose.
Murat Çalapkulu +4 more
doaj +1 more source